Gustavo Fabregat

Dr. Gustavo Fabregat

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2017 in Pain Medicine
Verified
Journal Article
Open access
PDF file
JAJose De Andres
Jose De Andres
VMVicente Monsalve-Dolz
Vicente Monsalve-Dolz
GFGustavo Fabregat
Gustavo Fabregat
VVVicente Villanueva-Perez
Vicente Villanueva-Perez
AHAnushik Harutyunyan
Anushik Harutyunyan
NSNerea Sanchis-Lopez
Nerea Sanchis-Lopez
Spinal cord stimulation (SCS) for patients with failed back surgery syndrome (FBSS) show variable results and limited to moderate evidence. In the last years the stimulation of high frequency (HF) has been considered as a better alternative in this pathology for its supposed benefits compared to the stimulation with conventional frequency (CF). To compare in one year follow-up, the efficacy of high-frequency SCS (HF) versus conventional frequency SCS (CF) on the patients with FBSS. Prospective, Randomized blind trial. Academic University Pain Medicine Center. Seventy eight patients with FBSS diagnosis based on internationally recognized criteria, and refractory to conservative therapy for at least 6 months, have been initially recruited, and Sixty subjects met the eligibility criteria and were randomized and scheduled for the trial phase.The patients were randomly assigned in either, one of the two groups: CF SCS or HF SCS. Within the study methods, special attention was paid to standardizing patient programming, so that these parameters would not impact the results.The trial period was considered successful if there was ?50% reduction in the NRS from baseline. A total of 55 subjects successfully completed all assessments during one year follow-up. Change patterns in scores do not differ based on high versus conventional frequency, with significant global average reduction at 1 year similarly for both groups. Among all the items included in the Short Form-12 questionnaire (SF-12), only the variations in the social function score between the instants t1 and t2 are somewhat higher in the high frequency group. The evolutionary pattern of the different parameters studied in our patients with FBSS does not differ according to their treatment by spinal stimulation, with conventional or high frequency, in one year follow-up.

12 January 2015 in Pain Practice
Verified
Journal Article
Closed access
PDF file
JAJose De Andres
Jose De Andres
NSNerea Sanchis‐Lopez
Nerea Sanchis‐Lopez
JAJuan Marcos Asensio‐Samper
Juan Marcos Asensio‐Samper
GFGustavo Fabregat
Gustavo Fabregat
VVVicente L. Villanueva‐Perez
Vicente L. Villanueva‐Perez
AMAna Minguez
Ana Minguez

31 October 2013 in The Korean Journal of Pain
Verified
Journal Article
Open access
PDF file
DEDe Andres Jose PhD FIPP EDRA
De Andres Jose PhD FIPP EDRA
PLPerotti Luciano
Perotti Luciano
VVVillanueva Vicente
Villanueva Vicente
AMAsensio Samper Juan Marcos
Asensio Samper Juan Marcos
GFGustavo Fabregat
Gustavo Fabregat
Jose DA, et al. Korean J Pain. 2013 Oct;26(4):336-346. https://doi.org/10.3344/kjp.2013.26.4.336

1 November 2013 in The Clinical Journal of Pain
Verified
Journal Article
Closed access
GFGustavo Fabregat
Gustavo Fabregat
JAJosé De Andrés
José De Andrés
VVVicente L. Villanueva-Pérez
Vicente L. Villanueva-Pérez
JAJuan M. Asensio-Samper
Juan M. Asensio-Samper
Botulinum toxin is a neurotoxin that has been widely used in chronic pain for the treatment of multiple conditions with a component of localized muscle spasm. Recent studies suggest that botulinum toxin is effective in the treatment of neuropathic pain syndromes such as postherpetic neuralgia or painful scars. We searched the PubMed and OvidSP databases. We also included cross-referencing bibliographies from primary and review articles. In this descriptive review, we evaluate the usefulness, safety, and potential pathophysiological mechanism of botulinum toxin type A for treatment of painful disorders with neuropathic component such as postherpetic neuralgia, diabetic neuropathy, or trigeminal neuralgia. On the basis of the analysis of the reports published in the literature, it would seem that fractioned peripheral subcutaneous and perineural injections of botulinum toxin type A may be useful for the treatment of various chronic pain conditions with neuropathic component.

21 June 2012 in Pain Practice
Verified
Journal Article
Closed access
PDF file
GFGustavo Fabregat
Gustavo Fabregat
JAJuan M. Asensio‐Samper
Juan M. Asensio‐Samper
SPStefano Palmisani
Stefano Palmisani
VVVicente L. Villanueva‐Pérez
Vicente L. Villanueva‐Pérez
JAJosé De Andrés
José De Andrés

22 August 2019
Verified
Book Chapter
Closed access
PDF file
JAJosé De Andrés
José De Andrés
RRRubén Rubio-Haro
Rubén Rubio-Haro
CACarmen De Andres-Serrano
Carmen De Andres-Serrano
JAJuan Marcos Asensio-Samper
Juan Marcos Asensio-Samper
GFGustavo Fabregat
Gustavo Fabregat